Solving difficult problems is MNTA’s raison d’etre, is it not?
Peptimmune, who filed a Citizen Petition with the FDA vis-à-vis generic Copaxone, claims that developing PK/PD assays for Copaxone is a solvable problem. Indeed, Peptimmune claims to have solved it. From page 12-13 of Peptimmune’s CP (http://www.peptimmune.com/uploads/news/peptimmune_citizen_petition_1012010.pdf ):
In short, Teva’s contention that this can’t be done is bullshit, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.